SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984655636> ?p ?o ?g. }

Showing items 1 to 100 of ±288 with 100 items per page.

W1984655636 endingPage "154" @default.
W1984655636 startingPage "128" @default.
W1984655636 abstract "The Breast JournalVolume 1, Issue 3 p. 128-154 Breast Cancer: A Template for Progress Through Multidisciplinary Cancer Research Judith E. Karp M.D., Corresponding Author Judith E. Karp M.D. National Cancer Institute, National Institutes of Health, Bethesda, MarylandAddress correspondence and reprint requests to: Judith E. Karp, M.D., National Cancer Institute, 9000 Rockville Pike, Building 31, Room 11A29, Bethesda, MD 20892, U.S.A.Search for more papers by this authorVivian W. Pinn M.D., Vivian W. Pinn M.D. Office of Research on Women's Health, National Institutes of Health, Bethesda, MarylandSearch for more papers by this author Judith E. Karp M.D., Corresponding Author Judith E. Karp M.D. National Cancer Institute, National Institutes of Health, Bethesda, MarylandAddress correspondence and reprint requests to: Judith E. Karp, M.D., National Cancer Institute, 9000 Rockville Pike, Building 31, Room 11A29, Bethesda, MD 20892, U.S.A.Search for more papers by this authorVivian W. Pinn M.D., Vivian W. Pinn M.D. Office of Research on Women's Health, National Institutes of Health, Bethesda, MarylandSearch for more papers by this author First published: May 1995 https://doi.org/10.1111/j.1524-4741.1995.tb00232.xCitations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Cancer Statistics Review 1973–1992. Bethesda ( MD ): National Cancer Institute, Division of Cancer Prevention and Control; 1995. NIH Publication #95–2789. 2 Coates RJ, Bradsfield DD, Wesley M, et al. Differences between black and white women with breast cancer in time from symptom recognition to medical consultation. J Natl Cancer Inst 1992; 84: 938– 50. 3 Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. JAMA 1994; 272: 947– 54. 4 Hunger CP, Redmond CK, Chen VW, et al. Breast cancer: Factors associated with stage at diagnosis in black and white women. J Natl Cancer Inst 1993; 85: 1129– 37. 5 Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692– 6. 6 Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266: 120– 2. 7 Hall JM, Lee MK, Newman B, et al. Linkage of earlyonset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684– 9. 8 Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66– 71. 9 Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 1994; 265: 2088– 90. 10 Weber BL. Clinical implications of basic research: susceptibility genes for breast cancer. N Engl J Med 1994; 331: 1523– 4. 11 Goldgar DE, Fields P, Lewis CM, et al. A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis. J Natl Cancer Inst 1994; 86: 200– 8. 12 Castilla LH, Couch FJ, Erdos MR, et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 1994; 8: 387– 91. 13 Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994; 8: 399– 404. 14 Simard J, Tonin P, Durocher F, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994; 8: 392– 8. 15 Borg A, Zhang Q-X, Johannsson O, Olsson H. High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. J Natl Cancer Inst 1994; 86: 792– 4. 16 Futreal PA, Soderkvist P, Marks JR, et al. Detection of frequent allelic loss of proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res 1992; 52: 2624– 7. 17 Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839– 64. 18 Skolnick MH, Cannon-Albright LA, Goldgar DE, et al. Inheritance of proliferative breast disease in breast cancer kindreds. Science 1990; 250: 1715– 20. 19 Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1233– 8. 20 Jolly KW, Malkin D, Douglass EC, et al. Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer. Oncogene 1994; 9: 97– 102. 21 Waldmann TA, Misiti J, Nelson DL, Kraemer CH. Ataxia-telangiectasia: a multisystem herditary disease with immunodeficiency, impaired organ maturation, X-ray hypersensitivity, and a high incidence of neoplasia. Ann Intern Med 1983; 99: 367– 79. 22 Swift M. Genetic aspects of ataxia-telangiectasia. Immunodeficiency 1990; 2: 67– 81. 23 Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831– 6. 24 Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987; 316: 1289– 94. 25 Nagasawa H, Kraemer KH, Shiloh Y, Little JB. Detection of ataxia telangiectasia heterozygous cell lines by postirradiation cumulative labeling index: measurements with coded samples. Cancer Res 1987; 47: 398– 402. 26 Lavin MF, Bennett I, Ramsay J. Identification of a potentially radiosensitive subgroup among patients with breast cancer. J Natl Cancer Inst 1994; 86: 1627– 34. 27 Swift M. Ionizing radiation, breast cancer, and ataxiatelangiectasia. J Natl Cancer Inst 1994; 86: 1571– 2. 28 Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD 45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587– 97. 29 Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780– 6. 30 Van Leeuwen FE, Klakman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312– 25. 31 Geller RB, Boone LB, Karp JE, et al. Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. Cancer 1989; 64: 629– 34. 32 Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Bystring K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76: 1083– 91. 33 Rubin CM, Arthur DC, Woods WG, et al. Therapyrelated myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood 1991; 11: 2982– 8. 34 Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-Epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 1992; 10: 1444– 51. 35 Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993; 85: 25– 31. 36 Yahalom J, Petrek JA, Biddinger PW, Kessler S, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 1992; 10: 1674– 81. 37 Motokura T, Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Devel 1993; 3: 5– 10. 38 Keyomarsi K, O'Leary N, Molnar G, et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54: 380– 5. 39 Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci 1993; 90: 1112– 6. 40 Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992; 257: 1958– 61. 41 Reed SI. G1-specific cyclins: in search of an S-phase-promoting factor. Trends Genet 1991; 7: 95– 9. 42 Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059– 65. 43 Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 1994; 91: 5291– 5. 44 Koff A, Ohtsuki M, Polyak K, Roberts JM, Massagué J. Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-β. Science 1993; 260: 536– 8. 45 Slingerland JM, Hengst L, Chin-Huei P, et al. A novel inhibitor of cyclin-cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 1994; 14: 3683– 94. 46 Knabbe C, Lippman ME, Wakefield LM, et al. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417– 28. 47 Wakefield LM, Sporn MB. Suppression of carcinogenesis: a role of TGF-beta and related molecules in the prevention of cancer. In: G Klein, ed. Tumor Suppressor Genes. New York : Marcel Dekker, 1990: 217– 43. 48 Butta A, MacLennan K, Flanders KC, et al. Induction of transforming growth factor in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261– 4. 49 Colletta AA, Wakefield LM, Howell FV, et al. Antioestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 405– 9. 50 Shackleford GM, MacArthur CA, Kwan HC, Varmus HE. Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4. Proc Natl Acad Sci USA 1993; 90: 740– 4. 51 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1994; 1: 27– 31. 52 Ornitz DM, Cardiff RD, Kuo A, Leder P. Int-2, an autocrine and/or ultra-short-range effector in transgenic mammary tissue transplants. J Natl Cancer Inst 1992; 84: 887– 92. 53 Zou Z, Anisowicz A, Hendrix MJC, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263: 526– 9. 54 Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200– 6. 55 Isola J, Visakorpi T, Holli K, Kallioniemi O-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 1109– 14. 56 Silvestrini R, Benini E, Daidone MG, et al. P53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 965– 70. 57 Cunningham JM, Ingle JN, Jung SH, et al. P53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J Natl Cancer Inst 1994; 86: 1871– 3. 58 Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992; 84: 845– 5. 59 Nguyen M, Watanabe H, Budson HE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356– 60. 60 Folkman J. Angiogenesis and breast cancer. J Clin Oncol 1994; 12: 441– 3. 61 Lee AKC, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990; 8: 1457– 65. 62 Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875– 86. 63 Wang JM, Kumar S, Pye D, Haboubi N, Al-Nakib L. Breast carcinoma: comparative study of tumor vasculature using two endothelial call markers. J Natl Cancer Inst 1994; 86: 386– 8. 64 Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1– 8. 65 Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454– 66. 66 Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994; 86: 614– 9. 67 Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582– 4. 68 Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177– 82. 69 Allred C, Clark GM, Tandon AK, Molina R, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599– 605. 70 Ciocca DR, Fujimura FK, Tandor AK, et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancer. J Natl Cancer Inst 1992; 84:16: 1279– 82. 71 Gasparini G, Gullick W, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992; 10: 686– 95. 72 Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049– 56. 73 Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. N Engl J Med 1994; 330: 1260– 6. 74 Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993; 11: 1936– 42. 75 Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992; 10: 1044– 8. 76 Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II node-positive breast carcinoma. N Engl J Med 1994; 330: 1253– 9. 77 Schneider J, Rubio MP, Barbazan MJ, et al. P-glyco-protein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994; 86: 850– 4. 78 Wiener JR, Kerns BJB, Harvey MR, et al. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst 1994; 86: 372– 8. 79 Dewailly E, Dodin S, Verreault R, et al. High organochlorine body burden in women with estrogen receptor-positive breast cancer. J Natl Cancer Inst 1994; 86: 232– 4. 80 Wolff MS, Toniolo PG, Lee EW, Rivera M, Dubin N. Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst 1993; 85: 648– 52. 81 Anderson LF. DDT and breast cancer: the verdict isn't in. J Natl Cancer Inst 1994; 86: 576– 7. 82 Krieger N, Wolff MS, Hiatt RA, Rivera M, Vogelman J, Orentreich N. Breast cancer and serum organochlorines: a prospective study among white, black and asian women. J Natl Cancer Inst 1994; 86: 589– 99. 83 MacMahon B. Pesticide residues and breast cancer J Natl Cancer Inst 1994; 86: 574. 84 Sugimura T, Nagao M, Wakabayashi K. Heterocyclic amines in cooked foods: candidates for causation of common cancers. J Natl Cancer Inst 1994; 86: 2– 4. 85 Davis CD, Ghoshal A, Schut HAJ, Snyderwine G. Metabolism of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by lactating fisher 344 rats and their nursing pups. J Natl Cancer Inst 1994; 10: 1065. 86 Daling JR, Malone KE, Voigt LF, White E, Weiss NS. Risk of breast cancer among young women: relationship of induced abortion. J Natl Cancer Inst 1994; 86: 1584– 92. 87 Hunter DJ, Manson JE, Colditz GA, et al. A prospective study of the intake of vitamins C, E and A and the risk of breast cancer. N Engl J Med 1993; 329: 234– 40. 88 Loomis DP, Savitz DA, Ananth CV. Breast cancer mortality among female electrical workers in the United States. J Natl Cancer Inst 1994; 86: 921– 2. 89 Newcomb PA, Storer BE, Longnecker MP, et al. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med 1994; 330: 81– 8. 90 Adami B-O, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989; 44: 833– 9. 91 Steinberg KK, Thacker SB, Smith J, et al. A meta-analysis in the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985– 90. 92 Toniolo PG, Levitz M, Jacquotte AZ, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995; 87: 190– 7. 93 White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst 1994; 86: 505– 14. 94 Colton T, Greenberg ER, Noller K, et al. Breast cancer in mothers prescribed diethylstilbestrol in pregnancy. JAMA 1993; 269: 2096– 100. 95 Bernstein L, Henderson BE, Hanisch R, et al. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86: 1403– 8. 96 Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993; 85: 1819– 27. 97 Kantor J, Irvine K, Adams S, Snoy P, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992; 52: 6917– 25. 98 Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen (CEA) epitopes from patients immunized with recombinant vaccinia-CEA (rV-CEA) vaccine. J Natl Cancer Inst. In press. 99 Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA1. J Immun 1993; 151: 1654– 62. 100 van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643– 6. 101 Boon T. Teaching the immune system to fight cancer. Sci Am 1993; 268(3): 82– 9. 102 Yanuck M, Carbone DP, Pendleton CD, et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993; 53: 3257– 61. 103 Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993; 259: 633– 8. 104 Spicer DV, Ursin G, Parisky YR, et al. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994; 86: 431– 6. 105 Feig SA. Hormonal reduction of mammographic densities: potential effects on breast cancer risk and performance of diagnostic and screening mammography. J Natl Cancer Inst 1994; 86: 408– 12. 106 Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 1991; 83: 1013– 6. 107 Fisher B, Redmond C. New perspective on cancer of the contralateral breast; a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 1991; 83: 1278– 80. 108 Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117– 20. 109 Marshall JS, Gordon NH, Hubay CA, Pearson OH. Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up. J Lab Clin Med 1987; 109: 300– 7. 110 Powles TJ, Tillyer CR, Jones AL, et al. Prevention of breast cancer with tamoxifen—an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990; 26: 680– 4. 111 Rutqvist LE, Cedermark B, Glas U, Mattsson A, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991; 83: 1299– 306. 112 Nayfield SG, Karp JE, Ford LG, Dorr, FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450– 9. 113 Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879– 86. 114 Kristensen B, Fjlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994; 12: 992– 7. 115 Love RR, Mazess RB, Barden HS, Epstein S, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852– 6. 116 Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82: 1327– 32. 117 Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86: 1534– 8. 118 Prentice RL. Tamoxifen as a potential preventive agent in healthy postmenopausal women. J Natl Cancer Inst 1990; 82: 1310– 1. 119 Fornander T, Hellström AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during and after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993; 85: 1850– 4. 120 Fornander T, Rutqvist LE, Cedrmark B, et al. Adjuvant tamoxifen in early-stage breast cancer: Effects on intercurrent morbidity and mortality. J Clin Oncol 1991; 9: 1740– 8. 121 Griffiths MFP. Tamoxifen retinopathy at low dosage. Am J Ophthalmol 1987; 15: 185– 6. 122 Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398– 406. 123 Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who receive adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286– 94. 124 Dragan YP, Xu YD, Pitot HC. Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev Med 1991; 20: 15– 26. 125 Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSPBP) B-14. J Natl Cancer Inst 1994; 86: 527– 37. 126 Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485– 90. 127 Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogeneis of familial colorectal cancer. Science 1993; 260: 812– 6. 128 Lynch HT, Lanspa S, Smyrk T, et al. Hereditary non-polyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural history and cancer control, Part I. Cancer Genet Cytogen 1991; 53: 143– 60. 129 Watson P, Vasen HFA, Mecklin JP, Järvinenh, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96: 516– 20. 130 Falk LA, De Benedetti F, Lohrey N, et al. Induction of transforming growth factor-β1 (TGF-β1) receptor expression and TGF-β1 protein production in retinoic acid-treated HL-60 cells: Possible TGF-β1 mediated autocrine inhibition. Blood 1991; 77: 1248– 55. 131 Anzano MA, Byers SW, Smith JM, et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 1994; 54: 4614. 132 Glick AB, Flanders KC, Danielpour D, et al. Retinoic acid induces transforming growth factor-β2 in cultured keratinocytes and mouse epidermis. Cell Reg 1989; 1: 87– 97. 133 Cobleigh MA, Dowlatshahi K, Deutsch TA, et al. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 1993; 11: 474– 7. 134 Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993; 11: 2036– 42. 135 Kelloff GJ, Boone CW, Steele VE, et al. Development of breast cancer chemopreventive drugs. J Cell Biochem Suppl 1993; 17G: 2– 13. 136 Wijngaarden TV, van, Pols HAP, Buurman CJ, et al. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Research 1994; 54: 5711– 7. 137 Chlebowski RT, Blackburn GL, Buzzard IM, et al. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. J Clin Oncol 1993; 11: 2072– 80. 138 NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer—screening, treatment, and follow-up. JAMA 1995; 273: 491– 7. 139 Elmore JG, Wells CK, Lee CH, et al. Variability in radiologist's interpretations of mammograms. N Engl J Med 1994; 331: 1493– 9. 140 Fletcher SW, Black W, Harris R, et al. Report of the international workshop on screening for breast cancer. J Natl Cancer Inst 1993; 85: 1644– 56. 141 Kaluzny AD, Rimer B, Harris R. The National Cancer Institute and guideline development: lessons from the breast cancer controversy. J Natl Cancer Inst 1994; 86: 901– 5. 142 Kattlove H, Liberati A, Keeler E, et al. Benefits and costs of screening and treatment for early breast cancer. JAMA 1995; 273: 142– 8. 143 Kerlikowske K, Grady D, Barclay J, et al. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 1993; 270: 2444– 50. 144 Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography: a meta-analysis. JAMA 1995; 273: 149– 54. 145 Kopans DB. Efficacy of screening mammography for women in their forties [editorial]. J Natl Cancer Inst 1994; 86: 1721– 30. 146 Kopans DB. The accuracy of mammographic interpretation [editorial]. N Engl J Med 1994; 331: 1521– 2. 147 Baines CJ. The Canadian National Breast Screening Study: a perspective on criticisms. Ann Intern Med 1994; 120: 326– 34. 148 Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59. Can Med Assoc J 1992; 147: 1477– 88. 149 Miller AB, Baines CJ, To T, et al. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 and 49 years. Can Med Assoc J 19" @default.
W1984655636 created "2016-06-24" @default.
W1984655636 creator A5027690428 @default.
W1984655636 creator A5040758762 @default.
W1984655636 date "1995-05-01" @default.
W1984655636 modified "2023-09-26" @default.
W1984655636 title "Breast Cancer: A Template for Progress Through Multidisciplinary Cancer Research" @default.
W1984655636 cites W1569141172 @default.
W1984655636 cites W1655423342 @default.
W1984655636 cites W1745189793 @default.
W1984655636 cites W1755920412 @default.
W1984655636 cites W1767955168 @default.
W1984655636 cites W1785581158 @default.
W1984655636 cites W1787821550 @default.
W1984655636 cites W1792161227 @default.
W1984655636 cites W1819160060 @default.
W1984655636 cites W1821465078 @default.
W1984655636 cites W1830273474 @default.
W1984655636 cites W1831283295 @default.
W1984655636 cites W1832673737 @default.
W1984655636 cites W1833833181 @default.
W1984655636 cites W1834547194 @default.
W1984655636 cites W1839907134 @default.
W1984655636 cites W1843618725 @default.
W1984655636 cites W1852147417 @default.
W1984655636 cites W1871768557 @default.
W1984655636 cites W1888411879 @default.
W1984655636 cites W1891831617 @default.
W1984655636 cites W1894983360 @default.
W1984655636 cites W1900945709 @default.
W1984655636 cites W1902814444 @default.
W1984655636 cites W1915395779 @default.
W1984655636 cites W1924784781 @default.
W1984655636 cites W1936024593 @default.
W1984655636 cites W1938529209 @default.
W1984655636 cites W1939846443 @default.
W1984655636 cites W1943552499 @default.
W1984655636 cites W1948079440 @default.
W1984655636 cites W1954070773 @default.
W1984655636 cites W1962197769 @default.
W1984655636 cites W1963820119 @default.
W1984655636 cites W1964540199 @default.
W1984655636 cites W1965332656 @default.
W1984655636 cites W1966823049 @default.
W1984655636 cites W1968287691 @default.
W1984655636 cites W1968351555 @default.
W1984655636 cites W1968780402 @default.
W1984655636 cites W1968788534 @default.
W1984655636 cites W1970296191 @default.
W1984655636 cites W1972103684 @default.
W1984655636 cites W1973690102 @default.
W1984655636 cites W1974893486 @default.
W1984655636 cites W1975411522 @default.
W1984655636 cites W1975973972 @default.
W1984655636 cites W1978089940 @default.
W1984655636 cites W1978718921 @default.
W1984655636 cites W1979669293 @default.
W1984655636 cites W1980530855 @default.
W1984655636 cites W1981476886 @default.
W1984655636 cites W1981534406 @default.
W1984655636 cites W1981570640 @default.
W1984655636 cites W1981965378 @default.
W1984655636 cites W1982577230 @default.
W1984655636 cites W1982942806 @default.
W1984655636 cites W1984077396 @default.
W1984655636 cites W1984172347 @default.
W1984655636 cites W1985202216 @default.
W1984655636 cites W1986179131 @default.
W1984655636 cites W1987880946 @default.
W1984655636 cites W1988365075 @default.
W1984655636 cites W1988567074 @default.
W1984655636 cites W1991026911 @default.
W1984655636 cites W1992405425 @default.
W1984655636 cites W1993614797 @default.
W1984655636 cites W1995959220 @default.
W1984655636 cites W1997226569 @default.
W1984655636 cites W1997715361 @default.
W1984655636 cites W1998553320 @default.
W1984655636 cites W2000000541 @default.
W1984655636 cites W2001753204 @default.
W1984655636 cites W2004935367 @default.
W1984655636 cites W2005542290 @default.
W1984655636 cites W2006987944 @default.
W1984655636 cites W2010120422 @default.
W1984655636 cites W2011701047 @default.
W1984655636 cites W2013010261 @default.
W1984655636 cites W2013472456 @default.
W1984655636 cites W2016138321 @default.
W1984655636 cites W2019498266 @default.
W1984655636 cites W2022059833 @default.
W1984655636 cites W2023459735 @default.
W1984655636 cites W2023843856 @default.
W1984655636 cites W2025571426 @default.
W1984655636 cites W2028037474 @default.
W1984655636 cites W2029344014 @default.
W1984655636 cites W2031211536 @default.
W1984655636 cites W2031281177 @default.
W1984655636 cites W2031450989 @default.